MENU
  • content validity:
    The CAR-T cell therapy is a gene engineering technology. It first transforms a fragment of scFv, an antibody capable of recognizing a tumor-specific antigen, then integrates the fragment into the transmembrane chain segment consisting of a series of molecules involved in T cell activation such as CD28, 4-1BB and CD3-ζ, forming a recombinant plasmid CAR. The CAR will be transduced into the T cells of a patient and cause them to express CAR. After the “re-coding”, a large amount of tumor-specific CAR-T cells will be generated to attack and eventually ablate the tumor.
  • content validity:
    Chimeric antigen receptor NK (CAR-NK) cell therapy is a gene engineering technology. It first transforms a fragment of scFv, an antibody capable of recognizing a specific tumor antigen and then integrates the fragment into the transmembrane chain segment composed of different combinations of molecules such as CD3-ζ, CD137, NKG2D and DAP10, forming a forming a recombinant plasmid CAR. The CAR will be transduced into the NK cells (from patients or healthy donors) and cause them to express CAR. After the “re-coding”, a large amount of tumor-specific CAR-NK cells will be generated to attack and eventually ablate the tumor.
ABOUT HRAIN
Overview
Awards
Corp Culture
NEWS
Hrain News
Media Library
D & M
Pipeline
R&D
Manufacturing
Clinical Layout
Clinical Center
Talent Construction
Join Us
Training & Development
Life
Contact Us
Contact Us
WE CHAT
WE CHAT
©2016 Hrain Biotechnology Co., Ltd. All rights reserved. Shanghai ICP NO.16016380 MIIT website
©2016 Hrain Biotechnology Co., Ltd. All rights reserved. Shanghai ICP NO.16016380 MIIT website